Dacomitinib (Dacomitinib) VS Osimertinib, which is the preferred drug for the treatment of non-small cell lung cancer?

When treating non-small cell lung cancer (NSCLC), especially EGFR mutation-positive patients, Dacomitinib (Dacomitinib) and Osimertinib (Osimertinib) are two frequently mentioned targeted therapy drugs. Although they all act on EGFR gene mutations, they have different pharmacological properties, clinical effects and side effects. Below is an in-depth comparative analysis of these two drugs.

Drug Overview

1.Dacomitinib (Dacomitinib)（Dacomitinib）

Pharmacological effects: As a second-generation EGFRtyrosine kinase inhibitor (TKI), dacomitinib (dacomitinib) effectively inhibits the growth and spread of tumor cells by blocking the autophosphorylation and signaling of the EGFR receptor.

Indications: Especially suitable for first-line treatment of EGFR mutation-positive NSCLC patients.

Common side effects: include skin reactions (rash, dryness, itching), gastrointestinal discomfort (nausea, diarrhea), fatigue, etc.

2.Osimertinib (Osimertinib)

Pharmacological effects: As a third-generation EGFR-TKI, osimertinib is unique in its ability to inhibit the EGFR T790M mutation, a common mutation that causes drug resistance.

Indications: Mainly used to treat NSCLC containing EGFR T790M mutation. It can be used as first-line treatment and can also be used to overcome other EGFR-TKI resistance.

Common side effects: Similar todacomitinib and include skin reactions, gastrointestinal problems, and potential cardiovascular and pulmonary toxicity.

Comparison of clinical effects

1.Effectiveness

Dacomitinib : In certain clinical trials, Dacomitinib demonstrated longer progression-free survival (PFS) and significant tumor control compared with traditional EGFR-TKI (such as gefitinib).

Osimertinib: Due to its specific inhibition of theEGFR T790M mutation, osimertinib performs well in patients with this mutation and is effective in combating drug resistance even after failure of first-line treatment.

2.Drug resistance

Dacomitinib : Patients may develop drug resistance after a period of treatment, including primary resistance and acquired resistance, the latter often associated with EGFR T790M and other mutations.

Osimertinib: Due to its ability to effectively inhibit the T790M mutation, osimertinib provides a new treatment option for patients who develop this mutation after other EGFR-TKI treatments.

Side Effect Comparison

1.Skin and gastrointestinal reactions

Dacomitinib (Dacomitinib) Both osimertinib and osimertinib may cause adverse reactions such as dry skin, itching, diarrhea, etc., but there may be differences in specific frequency and severity. Dacomitinib may cause more skin reactions early in treatment, while osimertinib may cause more significant gastrointestinal effects.

2.Cardiovascular and other toxicities

Osimertinib may sometimes display cardiovascular-related toxicities, such as cardiac arrhythmias, that require regular monitoring and management.

Selection basis and individualized treatment

1.EGFRMutation status

Osimertinib may be the first choice for patients with NSCLC harboring the T790M mutation.

For patients who do not have the T790M mutation but have EGFRsensitizing mutations, dacomitinib may be more appropriate.

2.Resistance and treatment history

For patients who have experienced otherEGFR-TKI treatments and developed resistance, especially those who have developed theEGFR T790M mutation, osimertinib may be more effective.

For patients who have not received EGFR-TKI treatment or are new to treatment, dacomitinib (dacomitinib) may be a more reasonable choice.

Side effects and individualized management

When selecting a treatment, factors such as the patient's overall health and strategies for preventing and managing side effects also need to be considered.

In summary,Dacomitinib (Dacomitinib)and osimertinib are important treatment options for EGFR mutation-positive patients in non-small cell lung cancer. The choice of which agent should be based on the patient's specific circumstances, mutational status, risk of resistance, and needs for individualized management of side effects. Physicians and patients should engage in thorough discussion and evaluation when formulating a treatment plan to ensure that the selected drug provides maximum efficacy while minimizing the impact on the patient's quality of life.